Literature DB >> 8704247

Evolution of blood coagulation activators and inhibitors in the healthy human fetus.

P Reverdiau-Moalic1, B Delahousse, G Body, P Bardos, J Leroy, Y Gruel.   

Abstract

Blood coagulation proteins were determined in 285 healthy fetuses from 19 to 38 weeks' gestation and compared with those of 60 normal full-term newborns and 40 adult controls. Prolongation of the coagulation screening tests, prothrombin time, activated partial prothrombin time, and thrombin clotting time, in fetuses throughout intrauterine life was explained by low levels of vitamin K-dependent factors (II, VII, IX, and X), contact factors (XI, XII, prekallikrein, and high-molecular-weight kininogen), factor V, factor VIII, and fibrinogen. Low levels of antithrombin III, heparin cofactor II, protein C and protein S, and tissue factor pathway inhibitor were also found, and these probably contributed to a satisfactory hemostatic balance. Some of these parameters were evaluated by both immunologic and functional assays to detect possible "fetal" proteins. An increase in factor levels was observed after the thirty-fourth week of intrauterine life for most of the coagulation activators and inhibitors, but only factors V and VIII reached adult values at birth. This study therefore showed that fetal hemostasis is a dynamic system that evolves gradually toward the neonatal state and then toward the adult state.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8704247

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

1.  Prothrombotic phenotype of protein Z deficiency.

Authors:  Z F Yin; Z F Huang; J Cui; R Fiehler; N Lasky; D Ginsburg; G J Broze
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

2.  Fondaparinux sodium does not cross the placental barrier: study using the in-vitro human dually perfused cotyledon model.

Authors:  Fabrice Lagrange; Jean-Luc Brun; Marie Christine Vergnes; Francis Paolucci; Teresa Nadal; Jean-Joel Leng; Marie Claude Saux; Bernard Bannwarth
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 3.  Anticoagulation in the young.

Authors:  Paul Monagle
Journal:  Heart       Date:  2004-07       Impact factor: 5.994

Review 4.  The neonatal coagulation system and the vitamin K deficiency bleeding - a mini review.

Authors:  Ewald Pichler; Ludwig Pichler
Journal:  Wien Med Wochenschr       Date:  2008

5.  The impact of intraoperative vasopressin infusion in complex neonatal cardiac surgery.

Authors:  Shinichi Nishibe; Miki Tsujita
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-09-07

6.  Anticoagulant action of melagatran: a comparison between neonates and adults using calibrated automated thrombography (CAT).

Authors:  Gerhard Cvirn; Christina Cimenti; Joerg Kutschera; Ulrika Ferstl; Thomas Wagner; Wolfgang Muntean; Gunther Jurgens; Siegfried Gallistl; Martin Koestenberger
Journal:  Eur J Pediatr       Date:  2006-09-19       Impact factor: 3.183

7.  Bloodless Repair for a 3.6 Kilogram Transposition of the Great Arteries with Jehovah's Witness Faith.

Authors:  Jeffery L Burnside; Todd M Ratliff; Ashley B Hodge; Daniel Gomez; Mark Galantowicz; Aymen Naguib
Journal:  J Extra Corpor Technol       Date:  2017-12

8.  Placental dermatan sulfate: isolation, anticoagulant activity, and association with heparin cofactor II.

Authors:  Tusar K Giri; Douglas M Tollefsen
Journal:  Blood       Date:  2005-12-08       Impact factor: 22.113

9.  Purpura fulminans in a newborn infant with galactosemia.

Authors:  Aysegul Zenciroglu; Mehmet Sah Ipek; Mustafa Aydin; Abdurrahman Kara; Nurullah Okumus; Mustafa Kilic
Journal:  Eur J Pediatr       Date:  2009-12-17       Impact factor: 3.183

10.  A premature infant with fetal myocardial and abdominal calcifications and factor V Leiden homozygosity.

Authors:  M G K Parker; G Webster; R M Insoft
Journal:  J Perinatol       Date:  2009-11       Impact factor: 2.521

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.